Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aconitate hydratase (commonly known as aconitase) is an iron-sulfur enzyme that catalyzes the stereospecific isomerization of citrate to isocitrate via the intermediate cis-aconitate, a critical step in the citric acid (TCA) cycle[1][3][4][6]. Aconitase contains a [4Fe-4S] iron-sulfur cluster essential for its catalytic activity and is widely expressed from bacteria to humans, with both mitochondria-specific (ACO2) and cytosolic (ACO1) isoforms in eukaryotes. By enabling the TCA cycle, aconitase plays a central role in aerobic energy metabolism. The enzyme is sensitive to oxidative stress due to its iron-sulfur prosthetic group, and its activity is a marker for mitochondrial health. Dysfunction or inhibition of aconitase contributes to metabolic diseases, neurodegenerative conditions, and cancer cell metabolism adaptations[1][4][6].
Inhibitors block the isomerization of citrate to isocitrate by binding the active site or disrupting the iron-sulfur cluster[1][4]. Drugs that target the enzyme block cellular energy metabolism and the TCA cycle.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aconitate hydratase (Aconitase).